{"id":37891,"date":"2017-02-27T08:45:51","date_gmt":"2017-02-27T13:45:51","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37891"},"modified":"2017-02-27T08:45:51","modified_gmt":"2017-02-27T13:45:51","slug":"viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891","title":{"rendered":"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Viking Therapeutics Inc (NASDAQ:VKTX)<\/strong> a clinical-stage biopharma firm focused on the advancement of novel treatments for endocrine and metabolic disorders, reported a deal with PoC Capital, LLC to support company&#8217;s preliminary clinical advancement of VK2809 in GSD Ia. The company intends to submit an Investigational New Drug application for VK2809 for the cure of GSD Ia and start a human proof-of-concept trial in 2H2017.<\/p>\n<h2 style=\"text-align: justify;\"><strong>The buzz<\/strong><\/h2>\n<p style=\"text-align: justify;\">Under the terms of the deal, PoC Capital will be accountable for compensating up to $1.8 million in costs linked with VK2809 clinical trials, comprising an intended proof-of-concept study in people with GSD Ia.\u00a0 In lieu, up to $1.8 million in VKTX shares will be released to PoC Capital. Viking&#8217;s deal with PoC Capital comes after the firm&#8217;s recent update of positive top-line report from a proof-of-concept trial of \u2018VK2809\u2019 in an in vivo plan of GSD Ia.<\/p>\n<p style=\"text-align: justify;\">The study report performed under a sponsored research deal between Viking and Duke University, showed that treatment with VK2809 resulted in statistically notable declines in major metabolic markers of GSD Ia. Also, mean liver triglyceride content was lowered by over 60% in VK2809-cured animals relative to vehicle-cured control animals, while mean liver weight was lowered by over 30% versus controls.<\/p>\n<p style=\"text-align: justify;\">Moreover, average liver weight as a part of total body weight dropped by almost 20% in treated versus control animals. The current trial is continuing to assess the impact of VK2809 on the disease markers. Detailed report will be presented at a suitable scientific conference.<\/p>\n<p style=\"text-align: justify;\">Brian Lian, Ph.D., the CEO of Viking, reported that they are delighted to enter into this deal with PoC Capital as it will permit them to conduct the preliminary clinical work assessing VK2809 in GSD Ia in a capital effective manner. They consider GSD Ia as an interesting development prospect for VK2809, where they can leverage previous human data demonstrating the drug candidate&#8217;s strong effect on plasma triglycerides, and recent report showing promising efficacy in an animal plan of the disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viking Therapeutics Inc (NASDAQ:VKTX) a clinical-stage biopharma firm focused on the advancement of novel treatments for endocrine and metabolic disorders, reported a deal with PoC [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":37892,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12331,12329,12330,12328],"stock_ticker":[],"class_list":["post-37891","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-brian-lian","tag-nasdaqvktx","tag-viking-therapeutics-inc","tag-viking-therapeutics-inc-nasdaqvktx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Viking Therapeutics Inc (NASDAQ:VKTX) a clinical-stage biopharma firm focused on the advancement of novel treatments for endocrine and metabolic disorders, reported a deal with PoC [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-27T13:45:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"204\" \/>\n\t<meta property=\"og:image:height\" content=\"88\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC\",\"datePublished\":\"2017-02-27T13:45:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png\",\"keywords\":[\"Brian Lian\",\"NASDAQ:VKTX\",\"Viking Therapeutics Inc\",\"Viking Therapeutics Inc (NASDAQ:VKTX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\",\"name\":\"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png\",\"datePublished\":\"2017-02-27T13:45:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png\",\"width\":204,\"height\":88,\"caption\":\"Viking Therapeutics Inc\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC - Wall Street PR","og_description":"Viking Therapeutics Inc (NASDAQ:VKTX) a clinical-stage biopharma firm focused on the advancement of novel treatments for endocrine and metabolic disorders, reported a deal with PoC [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-02-27T13:45:51+00:00","og_image":[{"width":204,"height":88,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png","type":"image\/png"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC","datePublished":"2017-02-27T13:45:51+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png","keywords":["Brian Lian","NASDAQ:VKTX","Viking Therapeutics Inc","Viking Therapeutics Inc (NASDAQ:VKTX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891","url":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891","name":"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png","datePublished":"2017-02-27T13:45:51+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Viking-Therapeutics-Inc.png","width":204,"height":88,"caption":"Viking Therapeutics Inc"},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/viking-therapeutics-inc-nasdaqvktx-updates-on-agreement-with-poc-capital-llc-37891#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics Inc (NASDAQ:VKTX) Updates On Agreement With PoC Capital, LLC"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37891"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37892"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37891"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}